Purpose: To evaluate three new approaches for staging severity of glaucomatous visual field defects using frequency doubling technology.

Patients And Methods: One hundred and four patients with either ocular hypertension or chronic glaucoma were tested with both standard automated perimetry (SAP, 30-2 Humphrey threshold test) and frequency doubling technology (N-30 threshold test). Standard automated perimetry results were classified into four groups (normal tests, early defects, moderate defects, and severe defects) using the Glaucoma Staging System. Frequency doubling technology tests were also classified in four groups using three different approaches: frequency doubling technology probability map analysis, considering the number and location of disturbed points, frequency doubling technology MD and PSD indices, graphed on a two-axis diagram (FDT Staging System), and an abnormality score, based on both the statistical significance and the spatial location of depressed points. A control group of 20 eyes from 20 normal subjects was also tested and classified in the same way. The Cohen Kappa was used to compare the level of agreement between the three frequency doubling technology methods of classification and the glaucoma staging system.

Results: Measure of agreement was 0.679 using probability map assessment, 0.793 using the frequency doubling technology staging system, and 0.663 using the abnormality score. The specificity rate was 95% for all three methods.

Conclusions: All the studied approaches were able to correctly stage the glaucomatous functional damage, but the frequency doubling technology staging system was the easiest and quickest method. Moreover, it is the only method that supplies information on the characteristics of the defect, without requiring any other time-consuming procedures.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00061198-200310000-00004DOI Listing

Publication Analysis

Top Keywords

frequency doubling
36
doubling technology
32
staging system
16
frequency
9
doubling
9
functional damage
8
technology
8
three approaches
8
standard automated
8
automated perimetry
8

Similar Publications

Background: The negative impact of COVID-19 pandemic on healthcare service utilization has been reported in several countries. In Gabon, data on the preparedness for future pandemic are lacking. The aim of the present study was to assess the trends of hospital attendance, malaria and self-medication prevalences as well as ITN use before and during Covid-19 first epidemic waves in a paediatric wards of a sentinel site for malaria surveillance, in Libreville, Gabon.

View Article and Find Full Text PDF

Background: Adalimumab is an effective treatment for juvenile idiopathic arthritis-associated uveitis. Data are scarce on the effects of discontinuing adalimumab after control of the disease had been reached. We aimed to assess efficacy and safety of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis.

View Article and Find Full Text PDF

Background: Cognitive decline is a significant concern for stroke survivors, affecting their quality of life and increasing their burden on the healthcare system. DL-3-n-butylphthalide (butylphthalide) has shown efficacy in the short-term treatment of various cognitive impairments. This study evaluated the efficacy of butylphthalide in preventing cognitive decline over a 12-month period in patients with ischaemic stroke.

View Article and Find Full Text PDF

Background: High prevalence of urinary tract infections (UTI), including cystitis, and concern for antimicrobial resistance justify safe and effective non-antibiotic therapies for prevention of recurrent UTI (rUTI). This study investigated the effect of a whole cranberry fruit powder supplement on incidence of culture-confirmed UTI (primary outcome) in females with rUTI history.

Methods: This multicenter, 6-month, randomized, placebo-controlled, double-blind study enrolled 150 healthy females (18-65 years, body mass index (BMI) >17.

View Article and Find Full Text PDF

Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.

Lancet Neurol

February 2025

Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada; Department of Cognitive Neurology, St Joseph's Health Care London, London, ON, Canada. Electronic address:

Background: No treatments exist for apathy in people with frontotemporal dementia. Previously, in a randomised double-blind, placebo-controlled, dose-finding study, intranasal oxytocin administration in people with frontotemporal dementia improved apathy ratings on the Neuropsychiatric Inventory over 1 week and, in a randomised, double-blind, placebo-controlled, crossover study, a single dose of 72 IU oxytocin increased blood-oxygen-level-dependent signal in limbic brain regions. We aimed to determine whether longer treatment with oxytocin improves apathy in people with frontotemporal dementia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!